Bioactive-Based Nanotherapeutics

• Autore: Sindhu Rakesh K
• Pubblicazione: Newark : , : John Wiley & Sons, Incorporated, , 2025; ©2025
• Edizione: 1st ed.
• Descrizione fisica: 1 online resource (771 pages)
• Altri autori: SinghSumitra YaparEvren Algin
• Nota di contenuto: Cover -- Series Page -- Title Page -- Copyright Page -- Contents -- Preface -- Chapter 1 Basics of Nano-Bioactive Compounds and Their Therapeutic Potential -- 1.1 Introduction -- 1.2 Therapeutic Potential of Bioactive Compounds -- 1.2.1 Alkaloids -- 1.2.1.1 Medicinal Use of Alkaloids as Bioactive Molecule -- 1.2.2 Antibiotics -- 1.2.2.1 Medicinal Use of Antibiotics as Bioactive Molecule -- 1.2.3 Mycotoxins -- 1.2.3.1 Medicinal Use of Mycotoxins as Bioactive Molecule -- 1.2.4 Growth Factors -- 1.2.4.1 Medicinal Use of Growth Factors as Bioactive Compounds -- 1.2.5 Phenolics -- 1.2.5.1 Medicinal Use of Phenolics as Bioactive Compounds -- 1.3 Extraction Techniques for Obtaining Bioactive Compound -- 1.4 Novel Delivery Approach for Bioactive Compounds -- 1.5 Electrospinning -- 1.6 Micro- and Nanoencapsulation of Bioactive Compounds -- 1.7 Polymeric Nanoparticles (NPs) -- 1.8 Solid Lipid Nanoparticles -- 1.9 Nanoemulsions -- 1.10 Nanocrystals -- 1.11 Phytosomes -- 1.12 Therapeutic Potential of Nano-Bioactive Compounds -- 1.13 Conclusion -- References -- Chapter 2 Recent Techniques for Isolation of Bioactive Components from Plants -- 2.1 Introduction -- 2.2 Extraction Methods -- 2.2.1 Ultrasound-Assisted Extraction (UAE) -- 2.2.2 Supercritical Fluid Extraction (SFE) -- 2.2.3 Microwave-Assisted Extraction (MAE) -- 2.2.4 Molecular Imprinting Technology (MIT) -- 2.3 Recent Chromatographic Methods -- 2.3.1 Liquid Chromatography (LC) and Gas Chromatography (GC) -- 2.3.2 High-Performance Liquid Chromatography (HPLC) and Tandem Mass Spectrometry (MS/MS) -- 2.3.3 Supercritical Fluid Chromatography (SFC) -- 2.3.4 Two-Dimensional Chromatographic Approaches -- 2.4 Applications of Two-Dimensional Chromatographic Approaches -- 2.5 Hyphenated Techniques -- 2.6 Conclusion -- References -- Chapter 3 Bioactive-Based Nanocarriers for Inflammatory Diseases. ; 3.1 Inflammation and Diseases -- 3.2 Nanocarriers as Drug Delivery System -- 3.3 Nanocarriers and Inflammation -- 3.4 Inflammation in Central Nervous System -- 3.4.1 Etiology of CNS Inflammation -- 3.4.2 The Blood-Brain Barrier (BBB) -- 3.4.3 Immune Response -- 3.4.4 Clinical Manifestations -- 3.4.5 Diagnosis and Therapeutic Approaches -- 3.4.6 Chronic Inflammation -- 3.5 Ophthalmological Inflammation -- 3.5.1 Causes of Ophthalmological Inflammation -- 3.5.2 Symptoms of Ophthalmological Inflammation -- 3.5.3 Diagnosis and Treatment -- 3.6 Cardiovascular Inflammation -- 3.6.1 Significance of Inflammation -- 3.6.2 Factors Contributing to Inflammation -- 3.6.3 Role of Cytokines and Chemokines -- 3.6.4 Distinguishing Acute and Chronic Inflammation -- 3.6.5 Consequences of Chronic Inflammation -- 3.6.6 Treatment and Prevention -- 3.6.7 Use of Biomarkers -- 3.6.8 Ongoing Research -- 3.6.9 Nanocarriers Used in the Treatment of Cardiovascular Inflammation -- 3.7 Respiratory Inflammation -- 3.7.1 Origins of Respiratory Inflammation -- 3.7.2 Forms of Respiratory Inflammation -- 3.7.3 Disorders Associated with Respiratory Inflammation -- 3.7.4 Symptoms of Respiratory Inflammation -- 3.7.5 Treatment and Management -- 3.7.6 Prevention -- 3.7.7 Nanocarriers Used for the Treatment of Respiratory Inflammation -- 3.8 Inflammation in Gastric System -- 3.8.1 Causes of Gastric Inflammation -- 3.8.2 Types of Gastric Inflammation -- 3.8.3 Symptoms of Gastric Inflammation -- 3.8.4 Complications -- 3.8.5 Diagnosis -- 3.8.6 Treatment and Management -- 3.8.7 Prevention -- 3.8.8 Nanocarriers Used for the Treatment of Gastric Inflammation -- 3.9 Excretory System Inflammation -- 3.9.1 Causes of Excretory System Inflammation -- 3.9.2 Types of Urinary Tract Inflammation -- 3.9.3 Symptoms of Excretory System Inflammation -- 3.9.4 Complications -- 3.9.5 Diagnosis. ; 3.9.6 Treatment and Management -- 3.9.7 Prevention -- 3.9.8 Nanocarriers Used for Treatment of Excretory System Inflammation -- 3.10 Inflammation of the Reproductive System -- 3.10.1 Causes of Reproductive System Inflammation -- 3.10.2 Types of Reproductive System Inflammation -- 3.10.3 Symptoms of Reproductive System Inflammation -- 3.10.4 Complications -- 3.10.5 Diagnosis -- 3.10.6 Treatment and Management -- 3.10.7 Prevention -- 3.10.8 Nanocarriers Used for the Treatment of Reproductive Inflammation -- 3.11 Inflammation Associated with Dermatology -- 3.11.1 Causes of Dermatological Inflammation -- 3.11.2 Types of Dermatological Inflammation -- 3.11.3 Symptoms of Dermatological Inflammation -- 3.11.4 Complications -- 3.11.5 Diagnosis -- 3.11.6 Treatment and Management -- 3.11.7 Prevention -- 3.11.8 Nanocarriers Used for the Treatment of Inflammation Related to Dermatology -- 3.12 Muscular Inflammation -- 3.12.1 Causes of Muscular Inflammation -- 3.12.2 Types of Muscular Inflammation -- 3.12.3 Symptoms of Muscular Inflammation -- 3.12.4 Complications -- 3.12.5 Diagnosis -- 3.12.6 Treatment and Management -- 3.12.7 Prevention -- 3.12.8 Nanocarriers Used for the Treatment of Muscular Inflammation -- 3.13 Skeletal Inflammation -- 3.13.1 Causes of Skeletal Inflammation -- 3.13.2 Types of Skeletal Inflammation -- 3.13.3 Symptoms of Skeletal Inflammation -- 3.13.4 Complications -- 3.13.5 Diagnosis -- 3.13.6 Treatment and Management -- 3.13.7 Prevention -- 3.13.8 Nanocarriers Used for the Treatment of Skeletal Inflammation -- 3.14 Applications of Nanocarriers in Inflammation -- 3.15 Conclusion -- References -- Chapter 4 Bioactive-Based Nanocarriers for Dermal Diseases -- 4.1 Introduction -- 4.2 Skin Anatomy and Physiology: Implications for Drug Delivery -- 4.2.1 Structure of the Skin Layers -- 4.2.2 Epidermis: The Protective Barrier. ; 4.2.3 Dermis: Structural Support and Vascular Network -- 4.2.4 Hypodermis: Adipose Tissue and Insulation -- 4.2.5 Appendages: Hair Follicles, Sweat Glands, and More -- 4.3 Barrier Functions of the Skin -- 4.4 Transdermal Permeation Challenges -- 4.5 Factors Influencing Dermal Drug Penetration -- 4.5.1 Physicochemical Properties of the Drug -- 4.5.2 Formulation and Carrier Design -- 4.5.3 Skin Hydration and Moisture -- 4.5.4 Skin Integrity and Barrier Disorders -- 4.5.5 Anatomical Site and Skin Thickness -- 4.5.6 Circulation and Blood Flow -- 4.5.7 Skin pH and Microenvironment -- 4.6 Role of Nanocarriers in Enhancing Drug Penetration -- 4.6.1 Nanocarrier Types and Properties -- 4.6.2 Encapsulation and Solubilization -- 4.6.3 Enhanced Skin Penetration -- 4.6.4 Targeted Drug Delivery -- 4.6.5 Controlled Release -- 4.6.6 Safety and Biocompatibility -- 4.7 Types of Bioactive-Based Nanocarriers -- 4.8 Design Principles and Fabrication Techniques -- 4.8.1 Formulation Considerations -- 4.8.2 Techniques for Fabricating Bioactive-Based Nanocarriers -- 4.9 Characterization of Bioactive-Based Nanocarriers -- 4.9.1 Physicochemical Characterization -- 4.9.1.1 Dynamic Light Scattering -- 4.9.1.2 Zeta Potential Measurement -- 4.9.1.3 Fourier-Transform Infrared Spectroscopy -- 4.9.2 Morphological Analysis -- 4.9.2.1 Transmission Electron Microscopy -- 4.9.2.2 Scanning Electron Microscopy -- 4.9.3 Drug Release Profiling -- 4.9.3.1 In Vitro Release Studies -- 4.9.3.2 Franz Diffusion Cells -- 4.9.4 Stability Assessment -- 4.9.4.1 Accelerated Stability Studies -- 4.9.4.2 Thermal Analysis -- 4.10 Applications in Diverse Dermal Diseases -- 4.10.1 Acne: Targeted Delivery of Anti-Inflammatory Agents -- 4.10.1.1 Anti-Inflammatory Agents for Acne Treatment -- 4.10.1.2 Enhanced Drug Penetration -- 4.10.2 Psoriasis: Immune Modulation and Skin Barrier Restoration. ; 4.10.2.1 Immune Modulation Through Nanocarriers -- 4.10.2.2 Restoring Skin Barrier Function with Nanocarriers -- 4.10.2.3 Synergy in Action: Combined Approach for Comprehensive Psoriasis Management -- 4.10.3 Skin Cancers: Localized Chemotherapy and Photodynamic Therapy -- 4.10.4 Atopic Dermatitis: Addressing Inflammation and Pruritus -- 4.10.5 Bioactive-Based Nanocarriers for Chronic Wounds -- 4.11 Preclinical Studies: In Vivo and In Vitro -- 4.12 Challenges and Future Directions -- 4.13 Conclusion -- References -- Chapter 5 Nano-Based Nasal Delivery of Biomacromolecules: A Myriad of Opportunities -- 5.1 Biomacromolecules -- 5.2 Characteristics of Biomacromolecules and Delivery Challenges -- 5.2.1 Physicochemical Properties -- 5.2.2 Stability -- 5.2.3 Immunogenicity -- 5.2.4 Administration Route -- 5.3 Opportunities of Nasal Route -- 5.4 Main Factors in Nasal Cavity Affecting Delivery of Biomacromolecules -- 5.4.1 Nasal Epithelium and Absorption -- 5.4.2 Mucus Layer and Mucociliary Clearance -- 5.4.3 Enzymatic Activity -- 5.4.4 Other Factors -- 5.5 Nano-Based Delivery Systems as an Efficient Strategy to Improve Intranasal Administration of Biomacromolecules -- 5.5.1 Lipid-Based Delivery Systems -- 5.5.1.1 Liposomes -- 5.5.1.2 Lipid Nanoparticles: Solid Lipid Nanocarriers and Nanostructured Lipid Carriers -- 5.5.1.3 Nanoemulsions -- 5.5.2 Polymer-Based Delivery Systems -- 5.5.2.1 Polymeric Nanoparticles -- 5.5.2.2 Polymeric Micelles -- 5.5.2.3 Polymeric Nanocomplexes -- 5.5.2.4 Dendrimers -- 5.5.3 Inorganic Material-Based Delivery Systems -- 5.6 Proof of Concept: Biomacromolecules Administered by Intranasal Nano-Based Delivery Systems -- 5.6.1 Insulin -- 5.6.2 Glucagon-Like Peptide-1 and Its Analogs -- 5.6.3 Thyrotropin-Releasing Hormone -- 5.6.4 Other Peptides and Proteins -- 5.6.5 Nucleic Acid Therapeutics -- 5.7 Safety Considerations. ; 5.8 Conclusion.
• Titolo autorizzato: Bioactive-Based Nanotherapeutics
• ISBN: 1-394-28734-8; 1-394-28733-X
• Formato: Materiale a stampa
• Livello bibliografico: Monografia
• Lingua di pubblicazione: Inglese
• Record Nr.: 9911019564903321
• Lo trovi qui: Univ. Federico II